keyword
MENU ▼
Read by QxMD icon Read
search

Clinical trial end point and surrogate

keyword
https://www.readbyqxmd.com/read/27913502/mrd-in-aml-does-it-already-guide-therapy-decision-making
#1
Gert Ossenkoppele, Gerrit Jan Schuurhuis
Prognostic factors determined at diagnosis are predictive for outcome whereas achievement of morphological complete remission (CR) is still an important end point during treatment. Residual disease after therapy may reflect the sum of all diagnosis and postdiagnosis resistance mechanisms/factors; its measurement could hypothetically be very instrumental for guiding treatment. The possibility of defining residual disease (minimal residual disease [MRD]) far below the level of 5% blast cells is changing the landscape of risk classification...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913493/novel-agents-in-follicular-lymphoma-choosing-the-best-target
#2
Laurie H Sehn
Outcomes in patients with follicular lymphoma (FL) have improved dramatically over the last decade. However, novel agents are greatly needed for those who exhibit treatment resistance, in order to minimize lifelong toxicity and to enable combinations that may allow us to achieve the elusive goal of cure. Biological advances have led to the discovery of a large number of potential therapeutic targets and the development of a plethora of novel agents designed to exploit these processes. Possible targets include tumor cell surface markers, key components of intracellular pathways and epigenetic mechanisms, and reactive cells of the microenvironment...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27900954/renin-angiotensin-aldosterone-system-blockade-in-diabetic-kidney-disease-a-critical-and-contrarian-point-of-view
#3
REVIEW
Mohamed E Elrggal, Shaaban M S Ahmed, Meguid El Nahas
Diabetes mellitus is the most common cause of end-stage renal disease (ESRD) worldwide. Diabetic kidney disease (DKD) is associated with high morbidity and cardiovascular mortality. A number of guidelines and recommendations have been issued over the years recommending the use of renin-angiotensin-aldosterone system (RAAS) blockade in the management of DKD. This critical analysis takes a contrarian view, based on a selection of key clinical trials in the field, to argue that albuminuria should not be considered a target for treatment but instead a surrogate marker of DKD progression...
November 2016: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/27881506/development-and-evolution-of-a-hierarchical-clinical-composite-end-point-for-the-evaluation-of-drugs-and-devices-for-acute-and-chronic-heart-failure-a-20-year-perspective
#4
Milton Packer
Traditional approaches to the assessment of new treatments for heart failure have generally evaluated individual components of the syndrome at fixed points in time or have relied on surrogate physiological measures that are poorly correlated with the clinical status of patients. Conventional time-to-event trials that focus on morbidity and mortality represent an important methodological advance, but they generally assign undue weight to clinical events of less importance and are insensitive to difference in functional capacity among individuals who do not experience a clinical event during follow-up...
November 22, 2016: Circulation
https://www.readbyqxmd.com/read/27846007/carotid-intima-media-thickness-as-a-cardiovascular-risk-factor-and-imaging-pathway-of-atherosclerosis
#5
Osmar Antonio Centurión
Assessment of carotid intima-media thickness (IMT) has emerged as a simple and noninvasive technique for measuring atherosclerotic burden. Although serum biomarkers have been linked to the risk of developing atherosclerosis, carotid IMT has the theoretical advantage of directly visualizing a final consequence of the disease itself, namely atherosclerosis in the vessel wall. The current widespread application of carotid IMT measurements has been based on the validity, standardization, and reproducibility of the measurement and the evidence that an increased carotid IMT can be regarded as an attractive biomarker of atherosclerosis and of increased cardiovascular risk, potentially useful as a therapeutic target in those at increased cardiovascular risk...
December 2016: Critical Pathways in Cardiology
https://www.readbyqxmd.com/read/27678348/challenges-of-advanced-hepatocellular-carcinoma
#6
REVIEW
Stefano Colagrande, Andrea L Inghilesi, Sami Aburas, Gian G Taliani, Cosimo Nardi, Fabio Marra
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging, clinical and biochemical parameters is routinely performed, a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer...
September 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27660042/a-medical-device-grade-t1-and-ecv-phantom-for-global-t1-mapping-quality-assurance-the-t1-mapping-and-ecv-standardization-in-cardiovascular-magnetic-resonance-t1mes-program
#7
Gabriella Captur, Peter Gatehouse, Kathryn E Keenan, Friso G Heslinga, Ruediger Bruehl, Marcel Prothmann, Martin J Graves, Richard J Eames, Camilla Torlasco, Giulia Benedetti, Jacqueline Donovan, Bernd Ittermann, Redha Boubertakh, Andrew Bathgate, Celine Royet, Wenjie Pang, Reza Nezafat, Michael Salerno, Peter Kellman, James C Moon
BACKGROUND: T1 mapping and extracellular volume (ECV) have the potential to guide patient care and serve as surrogate end-points in clinical trials, but measurements differ between cardiovascular magnetic resonance (CMR) scanners and pulse sequences. To help deliver T1 mapping to global clinical care, we developed a phantom-based quality assurance (QA) system for verification of measurement stability over time at individual sites, with further aims of generalization of results across sites, vendor systems, software versions and imaging sequences...
September 22, 2016: Journal of Cardiovascular Magnetic Resonance
https://www.readbyqxmd.com/read/27650765/using-serum-urate-as-a-validated-surrogate-end-point-for-flares-in-patients-with-gout-protocol-for-a-systematic-review-and-meta-regression-analysis
#8
Melanie B Morillon, Lisa Stamp, William Taylor, Jaap Fransen, Nicola Dalbeth, Jasvinder A Singh, Robin Christensen, Marissa Lassere
INTRODUCTION: Gout is the most common inflammatory arthritis in men over 40 years of age. Long-term urate-lowering therapy is considered a key strategy for effective gout management. The primary outcome measure for efficacy in clinical trials of urate-lowering therapy is serum urate levels, effectively acting as a surrogate for patient-centred outcomes such as frequency of gout attacks or pain. Yet it is not clearly demonstrated that the strength of the relationship between serum urate and clinically relevant outcomes is sufficiently strong for serum urate to be considered an adequate surrogate...
September 20, 2016: BMJ Open
https://www.readbyqxmd.com/read/27598745/systemic-treatment-for-advanced-hepatocellular-carcinoma-the-search-of-new-agents-to-join-sorafenib-in-the-effective-therapeutic-armamentarium
#9
Andrea Ribeiro de Souza, Maria Reig, Jordi Bruix
INTRODUCTION: Hepatocelullar carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite the implementation of screening programs for high-risk individuals, a significant proportion of patients present with advanced disease at the moment of diagnosis. AREAS COVERED: In this review we will focus in the current treatment of advanced HCC, the research that has been done in the past few years, the achievements and failures in this setting and future perspectives...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27557438/adult-stem-cell-therapy-and-heart-failure-2000-to-2016-a-systematic-review
#10
Patricia K Nguyen, June-Wha Rhee, Joseph C Wu
Importance: Stem cell therapy is a promising treatment strategy for patients with heart failure, which accounts for more than 10% of deaths in the United States annually. Despite more than a decade of research, further investigation is still needed to determine whether stem cell regenerative therapy is an effective treatment strategy and can be routinely implemented in clinical practice. Objective: To describe the progress in cardiac stem cell regenerative therapy using adult stem cells and to highlight the merits and limitations of clinical trials performed to date...
August 24, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27515695/moderator-s-view-treatment-of-iga-nephropathy-getting-comfortable-with-uncertainty
#11
Richard J Glassock
A Polar Views discussion by Pozzi and Rauen et al. on the interpretation and clinical application of the recently published Supportive Versus Immunosuppressive Therapy of Progressive IgA Nephropathy (STOP-IgAN) trial has elucidated important points concerning potential strengths and weaknesses of this landmark randomized trial. This critical examination of the impact of steroid monotherapy or steroid plus an immunosuppressive (IS) agent compared with 'supportive' therapy with inhibitors of the renin-angiotensin system (RAS) has enhanced our appreciation of the importance of rigorous application of titrated RAS inhibition in high-risk patients with persistent proteinuria >0...
August 11, 2016: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/27451020/progression-free-survival-as-a-surrogate-for-overall-survival-in-first-line-chemotherapy-for-advanced-pancreatic-cancer
#12
Tsuyoshi Hamada, Yousuke Nakai, Hiroyuki Isayama, Hideo Yasunaga, Hiroki Matsui, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Minoru Tada, Kazuhiko Koike
BACKGROUND: Overall survival (OS), as the primary end-point in first-line chemotherapy trials, requires a prolonged follow-up time and may be confounded by subsequent regimens. This study aimed to evaluate the correlation between OS and surrogate end-points (progression-free survival [PFS], response rate and disease control rate), and to identify a potential surrogate for OS in advanced pancreatic cancer. METHODS: Based on an electronic search, we identified randomized controlled phase II and III trials of first-line chemotherapy for advanced pancreatic cancer...
September 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27438806/discrepant-longitudinal-volumetric-and-metabolic-evolution-of-diffuse-intrinsic-pontine-gliomas-during-treatment-implications-for-current-response-assessment-strategies
#13
U Löbel, S Hwang, A Edwards, Y Li, X Li, A Broniscer, Z Patay
INTRODUCTION: Based on clinical observations, we hypothesized that in infiltrative high-grade brainstem neoplasms, such as diffuse intrinsic pontine glioma (DIPG), longitudinal metabolic evaluation of the tumor by magnetic resonance spectroscopy (MRS) may be more accurate than volumetric data for monitoring the tumor's biological evolution during standard treatment. METHODS: We evaluated longitudinal MRS data and corresponding tumor volumes of 31 children with DIPG...
October 2016: Neuroradiology
https://www.readbyqxmd.com/read/27416985/rationale-application-and-clinical-qualification-for-nt-probnp-as-a-surrogate-end-point-in-pivotal-clinical-trials-in-patients-with-al-amyloidosis
#14
REVIEW
G Merlini, I Lousada, Y Ando, A Dispenzieri, M A Gertz, M Grogan, M S Maurer, V Sanchorawala, A Wechalekar, G Palladini, R L Comenzo
Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is particularly lethal when the heart is involved. A significant obstacle in the development of treatments for patients with AL amyloidosis, as well as for those with any disease that is rare, severe and heterogeneous, has been satisfying traditional clinical trial end points (for example, overall survival or progression-free survival)...
October 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27416322/reliable-and-developmentally-appropriate-study-end-points-are-needed-to-achieve-drug-development-for-treatment-of-pediatric-pulmonary-arterial-hypertension
#15
H Sun, N Stockbridge, R L Ariagno, D Murphy, R M Nelson, W Rodriguez
OBJECTIVE: To identify suitable end points and surrogates for pediatric pulmonary arterial hypertension (PAH) as the lack of developmentally appropriate end point and clinical trials contribute to the unmet medical need. STUDY DESIGN: Reviewed the efficacy end points and surrogates for all trials (1995 to 2013) that were submitted to the Food and Drug Administration (FDA) to support the approval of PAH therapy and conducted literature search. RESULTS: An increase in the 6 min walking distance (6MWD) was used as a primary end point in 8/9 adult PAH trials...
December 2016: Journal of Perinatology: Official Journal of the California Perinatal Association
https://www.readbyqxmd.com/read/27348762/angiotensin-ii-receptor-inhibition-with-candesartan-to-prevent-trastuzumab-related-cardiotoxic-effects-in-patients-with-early-breast-cancer-a-randomized-clinical-trial
#16
Annelies H Boekhout, Jourik A Gietema, Bojana Milojkovic Kerklaan, Erik D van Werkhoven, Renske Altena, Aafke Honkoop, Maartje Los, Willem M Smit, Peter Nieboer, Carolien H Smorenburg, Caroline M P W Mandigers, Agnes J van der Wouw, Lonneke Kessels, Annette W G van der Velden, Petronella B Ottevanger, Tineke Smilde, Jaap de Boer, Dirk J van Veldhuisen, Ido P Kema, Elisabeth G E de Vries, Jan H M Schellens
IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether angiotensin II antagonist treatment with candesartan can prevent or ameliorate trastuzumab-related cardiotoxic effects, defined as a decline in left ventricular ejection fraction (LVEF) of more than 15% or a decrease below the absolute value 45%. DESIGN: This randomized, placebo-controlled clinical study was conducted between October 2007 and October 2011 in 19 hospitals in the Netherlands, enrolling 210 women with early breast cancer testing positive for human epidermal growth factor receptor 2 (HER2) who were being considered for adjuvant systemic treatment with anthracycline-containing chemotherapy followed by trastuzumab...
August 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27318129/nia-aa-staging-of-preclinical-alzheimer-disease-discordance-and-concordance-of-csf-and-imaging-biomarkers
#17
Stephanie J B Vos, Brian A Gordon, Yi Su, Pieter Jelle Visser, David M Holtzman, John C Morris, Anne M Fagan, Tammie L S Benzinger
The National Institute of Aging and Alzheimer's Association (NIA-AA) criteria for Alzheimer disease (AD) treat neuroimaging and cerebrospinal fluid (CSF) markers of AD pathology as if they would be interchangeable. We tested this assumption in 212 cognitively normal participants who have both neuroimaging and CSF measures of β-amyloid (CSF Aβ1-42 and positron emission tomography imaging with Pittsburgh Compound B) and neuronal injury (CSF t-tau and p-tau and structural magnetic resonance imaging) with longitudinal clinical follow-up...
August 2016: Neurobiology of Aging
https://www.readbyqxmd.com/read/27312947/mri-and-mre-for-non-invasive-quantitative-assessment-of-hepatic-steatosis-and-fibrosis-in-nafld-and-nash-clinical-trials-to-clinical-practice
#18
REVIEW
Parambir S Dulai, Claude B Sirlin, Rohit Loomba
Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of chronic liver disease, and its prevalence is rising worldwide. The occurrence of non-alcoholic steatohepatitis (NASH) is associated with a substantial increase in disease related morbidity and mortality. Accordingly, there has been a surge of innovation surrounding drug development in an effort to off-set the natural progression and long-term risks of this disease. Disease assessment within clinical trials and clinical practice for NAFLD is currently done with liver biopsies...
November 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27293870/bioresorbable-vascular-scaffolds-in-patients-with-acute-myocardial-infarction-a-new-step-forward-to-optimized-reperfusion
#19
Fernando Alfonso, Javier Cuesta, Teresa Bastante, Fernando Rivero, Marcos García-Guimaraes, Teresa Alvarado, Amparo Benedicto, Bernardo Cortese, Robert Byrne, Adnan Kastrati
Bioresorbable vascular scaffolds (BVS) represent a disruptive technology that has caused a new revolution in interventional cardiology. BVS appear to be particularly appealing in patients presenting with an acute myocardial infarction (MI). The available evidence on the value of BVS implantation in this challenging scenario is very promising but still limited. Results come from preliminary small observational studies, prospective registries that include a control group, and from scarce randomized clinical trials with surrogate mechanistic or angiographic primary end-points...
June 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27227813/stratifying-prostate-cancer-patients-by-relative-lymph-node-involvement-population-and-modeling-based-study
#20
Jan T Poleszczuk, Peter A Johnstone, Heiko Enderling
It is estimated that about 10% of new prostate cancer (PCa) cases are lymph node-positive (LN+). We have previously discussed the role of the inflection point (IP) of an inverse Gompertzian survival curve as a surrogate for disease incurability. In this study, we aimed to stratify curability of different patient cohorts with pathologically positive lymph nodes through modeling survival curves by different percentages of LN involvement (%LN+) postoperatively and calculating associated IPs. From the Surveillance, Epidemiology, and End Results (SEER) database, we selected LN+ PCa patients undergoing radical prostatectomy...
August 2016: Cancer Medicine
keyword
keyword
21226
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"